SciBase Holding AB (SE:SCIB)
:SCIB
Want to see SE:SCIB full AI Analyst Report?
SCIB Stock Chart & Stats
kr0.33
>-kr0.01(-1.65%)
At close: 4:00 PM EST
kr0.33
>-kr0.01(-1.65%)
Day’s Range― - ―
52-Week Rangekr0.17 - kr0.44
Previous CloseN/A
Volume1.41K
Average Volume (3M)318.73K
Market Cap
kr323.06M
Enterprise Valuekr146.72M
Total Cash (Recent Filing)kr22.60M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding828,365,200
10 Day Avg. Volume218,776
30 Day Avg. Volume318,725
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)kr66.85M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthMulti-year revenue growth from 9.5M to 40.5M through 2025 signals durable commercial traction for the Nevisense platform and improving market adoption. Sustained top-line expansion supports scale economies, larger installed base and rising recurring procedure volumes that underpin longer-term revenue visibility.
High Gross MarginsA ~67% gross margin in 2025 reflects attractive product economics and favorable unit profitability for device and consumable sales. High gross margins provide room for targeted commercial investment and suggest that as procedure volumes increase, operating leverage can meaningfully improve operating income over time.
Recurring Consumable Revenue ModelDependence on disposable consumables and service contracts creates recurring, procedure-linked revenue that grows with installed base. This annuity-like component improves revenue predictability and margin resilience long term, enabling monetization of clinical adoption beyond one-time system sales.
Bears Say
Widening Operating LossesOperating losses expanded sharply in 2025 despite revenue gains, indicating persistent high operating costs or intensive commercial spend. Continued large EBIT deficits threaten the path to sustainable profitability and imply ongoing dependence on external funding unless costs are brought under control or revenue scale accelerates materially.
Severe Negative Cash FlowDeep and deteriorating operating and free cash flow in 2025 reflect structural burn that limits self-funding of growth. Persistent negative cash generation raises refinancing and dilution risk, constrains strategic flexibility, and makes the business vulnerable if capital markets tighten or fundraising terms become unfavorable.
Balance-sheet ErosionA sharp drop in equity and shrinking assets in 2025 compress the capital base despite low debt. This erosion reduces financial resilience and limits the company's ability to absorb setbacks, invest in commercialization, or pursue partnerships without dilutive financing, increasing strategic and solvency risk over the medium term.
SciBase Holding AB News
SCIB FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was kr0.17 and its highest was kr0.44 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is kr323.06M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is May 07, 2026 which is in 17 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on Mar 13, 2026. The company reported -kr0.051 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.051.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 828,365,200 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -kr0.051 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.597%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in SE:SCIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (SCIB) is a Swedish medical technology company that specializes in developing innovative diagnostic solutions for skin cancer detection and monitoring. The company operates primarily in the healthcare sector, focusing on non-invasive and effective diagnostic tools. Its core products leverage advanced technology, particularly electrical impedance spectroscopy, to provide dermatologists and healthcare providers with real-time information to aid in the diagnosis of skin lesions, ultimately enhancing patient outcomes.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Arcoma AB
―
Neola Medical AB
―
Iconovo AB
―